Evidence map›Paper›PMID 35486894›Full record

ArticleMolecular pharmaceutics2022

Novel

Zheng Qiao, Jingli Xu, Rene Gonzalez, Yubin Miao

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Recent Advances inInternational journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zheng QiaoDepartment of Radiology, University of Colorado Denver, Aurora, Colorado 80045, United States.
Jingli XuDepartment of Radiology, University of Colorado Denver, Aurora, Colorado 80045, United States.
Rene GonzalezDepartment of Medical Oncology, University of Colorado Denver, Aurora, Colorado 80045, United States.
Yubin MiaoDepartment of Radiology, University of Colorado Denver, Aurora, Colorado 80045, United States.ORCID 0000-0002-6607-4403
University of Colorado Denver · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Novel Receptor-Targeting Peptides for Melanoma TherapyR01CA225837 · NCI · UNIVERSITY OF COLORADO DENVER · PI MIAO, YUBIN · 2018 to 2022
$1.9M
NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR002535NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA225837
6 · The paper itself

Abstract

The aim of this study was to evaluate the effect of linker on tumor targeting and biodistribution of

Indexed as

alpha-MSHMelanoma, ExperimentalAnimalsCell Line, TumorHeterocyclic Compounds, 1-RingKidneyLactamsMiceMice, Inbred C57BLReceptor, Melanocortin, Type 1Tissue Distribution1,4,7-triazacyclononane-N,N',N''-triacetic acidalpha-MSHHeterocyclic Compounds, 1-RingLactamsReceptor, Melanocortin, Type 164Cu-NOTAalpha-melanocyte-stimulating hormonelactam-cyclizedmelanocortin-1 receptormelanoma imaging and therapy

Identifiers

PMID35486894
PMCPMC10188253
OpenAlexW4225099646

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.